

## BRAF (V600E Mutant Specific) (Prognostic Marker) Antibody

Mouse Monoclonal Antibody [Clone V600E/1321]

Catalog No	Format	Size
673-MSM1-P0	Purified Ab with BSA and Azide at 200ug/ml	20 ug
673-MSM1-P1	Purified Ab with BSA and Azide at 200ug/ml	100 ug
673-MSM1-P1ABX	Purified Ab WITHOUT BSA at 1.0mg/ml	100 ug


Applications	Tested Dillution	Note
Western Blot (WB)	2-4ug/ml	

### Product Details


<b>Clone</b>	V600E/1321
<b>Gene Name</b>	BRAF
<b>Immunogen</b>	An eleven amino acid residue long synthetic peptide (aa596-606), corresponding to Cys-GLAT(E)KSRWSG from human BRAF protein. It was conjugated to KLH at the N-terminus.
<b>Host</b>	Mouse
<b>Clonality</b>	Monoclonal
<b>Isotype / Light Chain</b>	IgG1 / Kappa
<b>Mol. Weight of Antigen</b>	35kDa (predicted)
<b>Cellular Localization</b>	Cytoplasm.
<b>Species Reactivity</b>	Human
<b>Positive Control</b>	A431 Jurkat and HeLa cells. Human melanoma and colon carcinoma, Human Skeletal Muscles

\*Optimal dilution for a specific application should be determined.

### Product Images for BRAF (V600E Mutant Specific) (Prognostic Marker) Antibody



Western Blot Analysis of Human Skeletal Muscles tissue lysate using BRAF Mouse Monoclonal Antibody (V600E/1321).



SDS-PAGE Analysis of Purified BRAF Mouse Monoclonal Antibody (V600E/1321). Confirmation of Purity and Integrity of Antibody.

### Specificity & Comments

The BRAF gene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The BRAF V600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8% of all solid tumours, including 45% of papillary thyroid carcinomas, 40-60% of melanomas, 5-15% of colorectal adenocarcinomas, 35% of serous low grade and borderline ovarian carcinomas, 1-3% of non-small cell lung cancers, and 5-7% of cholangiocarcinomas. Furthermore, the BRAF V600E mutation is found in 100% of hairy cell leukaemia, 54% Erdheim-Chester disease, 38% of Langerhans cell histiocytoses and 60% of pleomorphic xanthoastrocytomas.

### Limitations and Warranty

This antibody is available for research use only and is not approved for use in diagnosis. There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

### Supplied As

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

### Storage and Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

### Research Areas

B Cell Markers, Bladder Cancer, Breast Cancer, Cardiovascular, Colon Cancer, Infectious Disease, MAPK Signaling, Signal Transduction